Pulmatrix Inc (PULM)

Over the past six months, Pulmatrix's stock has been significantly impacted by a proposed merger with Cullgen Inc. Key events include the merger agreement with Cullgen, divestment plans for the iSPERSE™ technology and related clinical programs, financial results announcements for Q3, Q2, and Q1 2025, a cross-license agreement with MannKind Corporation, and a significant decline in share price. The share price experienced a significant decline of 61.60% between January 8, 2025 and January 7, 2026.

Specific detailed information regarding the demand seasonality for Pulmatrix, Inc.'s products and services is not readily available. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to development milestones, partnerships, and potential future commercialization, rather than direct consumer demand for marketed products that might exhibit seasonal fluctuations.

Pulmatrix, Inc., founded in 2003 and based in Framingham, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing inhaled therapeutic products for pulmonary diseases and CNS disorders. The company's iSPERSE™ dry powder delivery platform aims to improve therapeutic delivery to the lungs. Key products and pipeline candidates include PUR1900 for allergic bronchopulmonary aspergillosis, PUR1800 for acute exacerbations in chronic obstructive pulmonary disease (AECOPD), and PUR3100 for acute migraine.

Pulmatrix, Inc. is headquartered in Framingham, Massachusetts, with a primary focus on product development in the United States. The company has an indirect international geographic footprint through licensing and collaboration agreements, such as the one with Cipla Technologies LLC for Pulmazole (PUR1900).

Pulmatrix's brand reputation has been shaped by its strategic corporate activities and clinical development progress. The proposed merger with Cullgen and divestment plans introduce uncertainty but positive developments such as FDA acceptance of an IND application for PUR3100 and positive Phase 1b results for PUR1800 contribute positively. The cross-license agreement with MannKind Corporation also validates the potential of Pulmatrix's iSPERSE™ technology.

Pulmatrix, Inc. has a mix of institutional and individual insider ownership. Institutional owners hold approximately 9.47% to 11.84% of the stock, with major shareholders including Renaissance Technologies Llc and Vanguard Group Inc. Insiders own a significant portion, around 17.83% to 186.07%, with Steven Gillis being the largest individual shareholder. Retail investors hold a very small percentage, approximately 0.00%.